Humanized Monoclonal Antibodies Derived from Chimpanzee Fabs Protect against Japanese Encephalitis Virus In Vitro and In Vivo

Goncalvez, Ana P.; Chien, Cheng-Hsin; Tubthong, Kamolchanok; Gorshkova, Inna; Roll, Carrie; Donau, Olivia K.; Schuck, Peter; Yoksan, Sutee; Wang, Sy-Dar; Purcell, Robert H.; Lai, Ching-Juh

doi:10.1128/jvi.00291-08

Cited by 72 publications

(59 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The chimpanzee animal model has played a key role in the study of several viral pathogens (22)(23)(24)(25)(26)(27)(28)(29)(30). During early HAV challenge experiments in nonhuman primates, it was determined that 10 4.5 -fold more virus was required to infect animals by the oral route compared with the i.v.…”

Section: Resultsmentioning

confidence: 99%

Chimpanzees as an animal model for human norovirus infection and vaccine development

Bok

Parra²,

Mitra³

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

209

196

View full text Add to dashboard Cite

Noroviruses are global agents of acute gastroenteritis, but the development of control strategies has been hampered by the absence of a robust animal model. Studies in chimpanzees have played a key role in the characterization of several fastidious hepatitis viruses, and we investigated the feasibility of such studies for the noroviruses. Seronegative chimpanzees inoculated i.v. with the human norovirus strain Norwalk virus (NV) did not show clinical signs of gastroenteritis, but the onset and duration of virus shedding in stool and serum antibody responses were similar to that observed in humans. NV RNA was detected in intestinal and liver biopsies concurrent with the detection of viral shedding in stool, and NV antigen expression was observed in cells of the small intestinal lamina propria. Two infected chimpanzees rechallenged 4, 10, or 24 mo later with NV were resistant to reinfection, and the presence of NV-specific serum antibodies correlated with protection. We evaluated the immunogenicity and efficacy of virus-like particles (VLPs) derived from NV (genogroup I, GI) and MD145 (genogroup II, GII) noroviruses as vaccines. Chimpanzees vaccinated intramuscularly with GI VLPs were protected from NV infection when challenged 2 and 18 mo after vaccination, whereas chimpanzees that received GII VLPs vaccine or a placebo were not. This study establishes the chimpanzee as a viable animal model for the study of norovirus replication and immunity, and shows that NV VLP vaccines could induce protective homologous immunity even after extended periods of time.

show abstract

Section: Resultsmentioning

confidence: 99%

Chimpanzees as an animal model for human norovirus infection and vaccine development

Bok

Parra²,

Mitra³

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

209

196

View full text Add to dashboard Cite

show abstract

“…The amino acid differences between the vaccine strains and the GI strains did not exceed 2.4 %, indicating that the difference may not influence the efficacy of the vaccines. Previous studies have identified individual residues within the E protein that are related to the recognition of JEV by neutralizing antibodies (Crill & Chang, 2004;Goncalvez et al, 2008;Kobayashi et al, 1985;Morita et al, 2001;Vogt et al, 2009;Wu et al, 2003). Although the sequence variation between the vaccine strains and GV strains do not correspond to epitope residues, only a limited number of residues could be responsible for the decreased neutralization ability of the vaccines against GV strains.…”

Section: Discussionmentioning

confidence: 99%

In vitro growth, pathogenicity and serological characteristics of the Japanese encephalitis virus genotype V Muar strain

Tajima

Yagasaki

Kotaki

et al. 2015

Journal of General Virology

View full text Add to dashboard Cite

The characteristics of genotype V Japanese encephalitis virus (GV JEV) remain poorly understood as only two strains have been isolated to date. In this study, we examined the effects of the GV JEV Muar strain on in vitro growth and pathogenicity in mice; we also evaluated the efficacy of inactivated JEV vaccines against the Muar strain. Although growth of the Muar strain in mouse neuroblastoma N18 cells was clearly worse than that of the GIII Beijing-1 and GI Mie/41/2002 strains, neuroinvasiveness of the Muar strain was similar to that of the Beijing-1 strain and significantly higher than that of the Mie/41/2002 strain. The results of a plaque reduction neutralization test suggested that the neutralization ability of the JEV vaccines against the Muar strain was reduced compared with the GI and GIII strains. However, the protection potency of the JEV vaccine against the Muar strain was similar to that for the Beijing-1 strain in mice. Our data indicate that GV JEV has unique growth, virulence and antigenicity features.

show abstract

“…The importance of a vigorous, virus-specific, humoral immune response in ameliorating and preventing illness has been documented in human cases of JE Libraty et al, 2002;McCallum, 1991) and in animal models by administration of antibody prior or subsequent to infection with JEV (Goncalvez et al, 2008;Gupta et al, 2003;Kimura-Kuroda & Yasui, 1988;Zhang et al, 1989). We have shown that mice genetically defective in B cells and antibody ( MT-/-) develop uncontrolled viremia, viral persistence in peripheral tissues, rapid and widespread viral dissemination into the CNS, and early uniform mortality (Larena et al, 2011).…”

Section: B Cellsmentioning

confidence: 99%

“…The latter can control JEV infection by their complement-mediated cytolytic potential (Krishna et al, 2009;Lin et al, 2008b;Lin et al, 1998). Antibody neutralizes flavivirus infectivity with high efficiency mainly by interfering with early steps of the viral entry pathway, including attachment, internalisation, and fusion (Butrapet et al, 1998;Crill & Roehrig, 2001;Goncalvez et al, 2008;Nybakken et al, 2005).…”

Section: B Cellsmentioning

confidence: 99%

Immunobiology of Japanese Encephalitis Virus

Larena¹,

Lobigs²

2011

Flavivirus Encephalitis

View full text Add to dashboard Cite

Humanized Monoclonal Antibodies Derived from Chimpanzee Fabs Protect against Japanese Encephalitis Virus In Vitro and In Vivo

Cited by 72 publications

References 66 publications

Chimpanzees as an animal model for human norovirus infection and vaccine development

Chimpanzees as an animal model for human norovirus infection and vaccine development

In vitro growth, pathogenicity and serological characteristics of the Japanese encephalitis virus genotype V Muar strain

Immunobiology of Japanese Encephalitis Virus

Contact Info

Product

Resources

About